INTRODUCTION Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe, although not very common, clinical skin pictures that are usually related to the use of medication. Several antiepileptic drugs, including phenytoin, have been linked to SJS/TEN. Some authors have described an increased risk for SJS/TEN when phenytoin is associated to radiotherapy, while others report the possibility of an increased risk when it is associated to corticoids. DEVELOPMENT. This work includes a review of the spontaneous reports of suspected cases of phenytoin-linked SJS/TEN recorded in the database of the Pharmacovigilance Department at Pfizer-España between October 2000 and December 2003. Nine cases compatible with SJS/TEN were found; four occurred in cancer patients that had received radiotherapy, three of whom were also treated with corticoids. DISCUSSION AND
CONCLUSIONS After reviewing the spontaneously reported cases in the database of the Pharmacovigilance Department at Pfizer-España as well as the cases in the literature, it can be concluded that when it comes to indicating a prophylactic antiepileptic treatment for cancer patients with cerebral metastasis, the clinician must take into account the existence of a greater risk of SJS/TEN if the patient is going to receive radiotherapy. If the patient already presents a history of skin rashes following administration of an antiepileptic drug, care must be taken in choosing another because phenytoin together with carbamazepine, phenobarbital and lamotrigine have all been linked to SJS/TEN. Cross-sensitivity of carbamazepine and barbiturates with phenytoin has been observed. Gabapentin and valproic acid could be considered as therapeutic options in such cases.
KeywordsAntiepileptic drugsCorticoidsPhenytoinRadiotherapyStevens-Johnson syndromeToxic epidermal necrolysisCategoriesEpilepsias y síndromes epilépticos
FULL TEXT(solo disponible en lengua castellana / Only available in Spanish)
Si ya es un usuario registrado en Neurologia, introduzca sus datos de inicio de sesión.
Rellene los campos para registrarse en Neurologia.com y acceder a todos nuestros artículos de forma gratuita
¿Olvidó su contraseña? Introduzca su correo electrónico y le haremos llegar una nueva
¡CONVIÉRTASE EN USUARIO PREMIUM DE NEUROLOGIA.COM!
Al hacerse premium, está apoyándonos para que Revista de Neurología
siga siendo uno de los referentes de habla hispana en la difusión del
conocimiento en neurociencias. ¡Gratuita tanto para autores como para
todos los usuarios de la web!
Además, por convertirte en usuario premium, recibirá las siguientes ventajas:
Plaza asegurada en todos nuestros Másteres (www.ineurocampus.com)
Descuento del 5% en los cursos de “Actualización en Neurología”, la FMC que estará disponible próximamente en la web.
Descarga gratuita en formato PDF dos de las obras con más éxito publicadas por Viguera Editores:
Oromotors Disorders in childhood (M. Roig-Quilis; L. Pennington)
Manual de Neuropsicología 2ª ed. (J. Tirapu-Ustárroz; M. Ríos-Lago; F. Maestú)
El precio para hacerse Premium durante el periodo de un año es de 5€, que podrá pagar a continuación a través de una pasarela de pago seguro con tarjeta de crédito, transferencia bancaria o PayPal: